Nedosiran Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 80 mg, 160 mg
Reference Brands: Ryplazim (USA)
Category:
Nephrology
Nedosiran is available in Injection
and strengths such as 80 mg, 160 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Nedosiran is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Nedosiran can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Nedosiran, marketed under the brand name Rivfloza, is a targeted RNA interference (RNAi) therapy used for the treatment of primary hyperoxaluria type 1 (PH1), a rare genetic disorder characterized by excessive oxalate production that can progressively damage the kidneys. Developed by Dicerna Pharmaceuticals, nedosiran is an LDHA-directed small interfering RNA that specifically silences the hepatic lactate dehydrogenase A (LDHA) gene, reducing oxalate synthesis at its source.
Rivfloza is indicated for patients aged nine years and older with PH1 who have relatively preserved kidney function. By lowering urinary oxalate levels, nedosiran helps prevent kidney stone formation, nephrocalcinosis, and long-term renal complications associated with the disease. The therapy is administered via subcutaneous injection, typically on a monthly or individualized dosing schedule, providing a convenient and precise approach to managing this rare metabolic condition.
Through its innovative RNAi mechanism, Rivfloza offers a disease-modifying option for patients with PH1, addressing the underlying cause of oxalate overproduction rather than just managing symptoms. Its targeted action, combined with clinical efficacy and favorable safety profile, positions nedosiran as a significant advancement in the treatment of primary hyperoxaluria, improving patient outcomes and long-term kidney health.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing